Xzid M 80mg/500mg Tablet XR is a combination oral antidiabetic medication containing Gliclazide 80mg and Metformin 500mg in an extended-release formulation. It is primarily indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled by diet, exercise, and monotherapy. Gliclazide, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake. The extended-release formulation allows for a gradual release of active ingredients, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. Xzid M is typically administered once daily with meals to optimize absorption and minimize hypoglycemia risk. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Regular monitoring of blood glucose, renal function, and hematologic parameters is recommended during therapy. Dose adjustments may be necessary based on glycemic response and tolerability. This combination therapy offers a synergistic approach to glycemic management, improving patient adherence and clinical outcomes in type 2 diabetes mellitus.